These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29045152)

  • 1. Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators.
    Boehm M; Beaumont K; Jones R; Kalgutkar AS; Zhang L; Atkinson K; Bai G; Brown JA; Eng H; Goetz GH; Holder BR; Khunte B; Lazzaro S; Limberakis C; Ryu S; Shapiro MJ; Tylaska L; Yan J; Turner R; Leung SSF; Ramaseshan M; Price DA; Liras S; Jacobson MP; Earp DJ; Lokey RS; Mathiowetz AM; Menhaji-Klotz E
    J Med Chem; 2017 Dec; 60(23):9653-9663. PubMed ID: 29045152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrocyclic Tetramers-Structural Investigation of Peptide-Peptoid Hybrids.
    Herlan CN; Sonnefeld A; Gloge T; Brückel J; Schlee LC; Muhle-Goll C; Nieger M; Bräse S
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the cell permeability of bicyclic peptoids and bicyclic peptide-peptoid hybrids.
    Wang HM; Seo CD; Lee KJ; Park JH; Lim HS
    Bioorg Chem; 2022 Oct; 127():105976. PubMed ID: 35777233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptoid-peptide hybrids as potent novel melanocortin receptor ligands.
    Kruijtzer JA; Nijenhuis WA; Wanders N; Gispen WH; Liskamp RM; Adan RA
    J Med Chem; 2005 Jun; 48(13):4224-30. PubMed ID: 15974575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists.
    Liu F; Stephen AG; Waheed AA; Freed EO; Fisher RJ; Burke TR
    Bioorg Med Chem Lett; 2010 Jan; 20(1):318-21. PubMed ID: 19914066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptoid macrocycles: making the rounds with peptidomimetic oligomers.
    Yoo B; Shin SB; Huang ML; Kirshenbaum K
    Chemistry; 2010 May; 16(19):5528-37. PubMed ID: 20414912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.
    Bockus AT; Lexa KW; Pye CR; Kalgutkar AS; Gardner JW; Hund KC; Hewitt WM; Schwochert JA; Glassey E; Price DA; Mathiowetz AM; Liras S; Jacobson MP; Lokey RS
    J Med Chem; 2015 Jun; 58(11):4581-9. PubMed ID: 25950816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis.
    Menhaji-Klotz E; Hesp KD; Londregan AT; Kalgutkar AS; Piotrowski DW; Boehm M; Song K; Ryder T; Beaumont K; Jones RM; Atkinson K; Brown JA; Litchfield J; Xiao J; Canterbury DP; Burford K; Thuma BA; Limberakis C; Jiao W; Bagley SW; Agarwal S; Crowell D; Pazdziorko S; Ward J; Price DA; Clerin V
    J Med Chem; 2018 Apr; 61(8):3685-3696. PubMed ID: 29627981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translating antibody-binding peptides into peptoid ligands with improved affinity and stability.
    Bordelon T; Bobay B; Murphy A; Reese H; Shanahan C; Odeh F; Broussard A; Kormos C; Menegatti S
    J Chromatogr A; 2019 Sep; 1602():284-299. PubMed ID: 31230875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugation of a novel Apaf-1 inhibitor to peptide-based cell-membrane transporters: effective methods to improve inhibition of mitochondria-mediated apoptosis.
    Orzáez M; Mondragón L; Marzo I; Sanclimens G; Messeguer A; Pérez-Payá E; Vicent MJ
    Peptides; 2007 May; 28(5):958-68. PubMed ID: 17408805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the proline residue on ligand binding of neurotensin receptor 2 (NTS2)-selective peptide-peptoid hybrids.
    Held C; Hübner H; Kling R; Nagel YA; Wennemers H; Gmeiner P
    ChemMedChem; 2013 May; 8(5):772-8. PubMed ID: 23532897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Triazolium-Grafted Peptidomimetic Macrocycles with Facial Amphipathicity to Target Pathogenic Bacteria.
    Guerinot C; Malige M; Charbonnel N; Malosse K; Jouffret L; Taillefumier C; Roy O; Forestier C; Faure S
    Org Lett; 2024 May; 26(19):4088-4092. PubMed ID: 38709636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.
    Yang W; Wang Y; Lai A; Clark CG; Corte JR; Fang T; Gilligan PJ; Jeon Y; Pabbisetty KB; Rampulla RA; Mathur A; Kaspady M; Neithnadka PR; Arumugam A; Raju S; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Chacko SA; Bozarth JM; Wu Y; Crain EJ; Wong PC; Seiffert DA; Luettgen JM; Lam PYS; Wexler RR; Ewing WR
    J Med Chem; 2020 Jul; 63(13):7226-7242. PubMed ID: 32456431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.
    Zhang X; Glunz PW; Johnson JA; Jiang W; Jacutin-Porte S; Ladziata V; Zou Y; Phillips MS; Wurtz NR; Parkhurst B; Rendina AR; Harper TM; Cheney DL; Luettgen JM; Wong PC; Seiffert D; Wexler RR; Priestley ES
    J Med Chem; 2016 Aug; 59(15):7125-37. PubMed ID: 27455395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lead discovery and optimization strategies for peptide macrocycles.
    Bhat A; Roberts LR; Dwyer JJ
    Eur J Med Chem; 2015 Apr; 94():471-9. PubMed ID: 25109255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
    Li D; Zhang X; Ma X; Xu L; Yu J; Gao L; Hu X; Zhang J; Dong X; Li J; Liu T; Zhou Y; Hu Y
    J Med Chem; 2018 Oct; 61(20):9177-9204. PubMed ID: 30265557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity oriented one-pot synthesis of complex macrocycles: very large steroid-peptoid hybrids from multiple multicomponent reactions including bifunctional building blocks.
    Wessjohann LA; Voigt B; Rivera DG
    Angew Chem Int Ed Engl; 2005 Jul; 44(30):4785-90. PubMed ID: 15988773
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.
    Hoveyda HR; Marsault E; Gagnon R; Mathieu AP; Vézina M; Landry A; Wang Z; Benakli K; Beaubien S; Saint-Louis C; Brassard M; Pinault JF; Ouellet L; Bhat S; Ramaseshan M; Peng X; Foucher L; Beauchemin S; Bhérer P; Veber DF; Peterson ML; Fraser GL
    J Med Chem; 2011 Dec; 54(24):8305-20. PubMed ID: 22106937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a metabolically stable neurotensin receptor 2 (NTS2) ligand.
    Held C; Plomer M; Hübner H; Meltretter J; Pischetsrieder M; Gmeiner P
    ChemMedChem; 2013 Jan; 8(1):75-81. PubMed ID: 23097347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-peptide/beta-peptoid chimeras.
    Olsen CA; Bonke G; Vedel L; Adsersen A; Witt M; Franzyk H; Jaroszewski JW
    Org Lett; 2007 Apr; 9(8):1549-52. PubMed ID: 17352488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.